101 – 110 of 200
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status.
(
- Contribution to journal › Article
-
Mark
Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome.
(
- Contribution to journal › Article
-
Mark
The impact of translocations and gene fusions on cancer causation.
(
- Contribution to journal › Scientific review
-
Mark
Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
(
- Contribution to journal › Article
-
Mark
Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12).
(
- Contribution to journal › Article
- 2006
-
Mark
Characterisation of dic(9;20)(p11-13;q11) in childhood B-cell precursor acute lymphoblastic leukaemia by tiling resolution array-based comparative genomic hybridisation reveals clustered breakpoints at 9p13.2 and 20q11.2
(
- Contribution to journal › Article
-
Mark
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia
2006) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 30(8). p.1043-1047(
- Contribution to journal › Article
-
Mark
FISH mapping of i(7q) in acute leukemias and myxoid liposarcoma reveals clustered breakpoints in 7p11.2 : implications for formation and pathogenetic outcome of the idic(7)(p11.2)
(
- Contribution to journal › Article
-
Mark
Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia.
(
- Contribution to journal › Article
-
Mark
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
(
- Contribution to journal › Article